The PennZone

WILMINGTON, Del. - PennZone -- Biophysical Therapeutics, a Delaware company, announces the launch of its consumer longevity brand called IF1.

It is currently accepting pre-orders for its first product, an anti-aging skin moisturizer available at www.IF1.skin. Only 500 units are available in the initial production run, retailing at $120 apiece.

This moisturizer is distinctive in incorporating leading-edge longevity science, and is further distinct, since the profit from its sales will feed back to fund the company's drug programs, which include drugs against cancer, age-related diseases (such as Alzheimer's disease), and aging itself.

The company was founded in 2022 by Dr. Michael Forrest, a Cambridge University biochemistry graduate with a Ph.D. in computer science, and is advised by Professor George Church of Harvard Medical School. Its specialty is computational biology and especially biophysical modeling, which is mathematical modeling of the physics and chemistry of a biological system, and the company is named after this approach. Unusually for a computational biology company, it has actually delivered new experimentally-validated drugs working as predicted in vivo, protected by granted patents.

More on The PennZone

• OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
• Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
• The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
• Pittsburgh Family Law Firm Pollock Begg Celebrates 16th Consecutive Best Law Firms Ranking
• Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration

The science behind the company's new anti-aging skin moisturizer is its conclusion regarding why different mammal species can have such different lifespans, for example, a mouse maximally lives 4 years whereas a bowhead whale can live centuries longer. This conclusion is complex but it distills to simplicity - species with more IF1 protein live longer. Indeed, the company has shown that increasing IF1 protein in mice reduces aging as measured by an aging biomarker.

People already buy anti-aging skincare. Indeed, it is already a $70B market and growing. This bodes well for this new brand that leverages differentiated anti-aging science from leading anti-aging scientists, which will in turn fund them to advance science and medicine. Economists calculate that the economic benefit of slower aging, to the USA alone, is $38T per year of increased life expectancy.

Dr. Forrest says: "Our IF1 brand brings leading-edge anti-aging science to skincare. This is just part of our mission to save, improve, and extend lives at mass scale."

More on The PennZone

• A Powerful Encounter Awaits Philadelphia: Dr. Mattie Nottage Joins Brother Marcus on Air
• Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
• Beyond Spots & Dots Spreads Holiday Cheer at Old Economy Village's Festival of Trees
• ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!
• New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc

The IF1 anti-aging skin moisturizer is available for pre-order now exclusively at www.IF1.skin.

About Biophysical Therapeutics
Biophysical Therapeutics is a Delaware-based biotechnology company that uses computational biology, especially biophysical modeling, to discover new fundamental biology and design new drugs. Its primary targets are cancer, the diseases of aging (e.g., Alzheimer's disease), and aging itself. The company has a pipeline of experimentally-validated new drugs and a portfolio of granted patents. It owns a longevity skincare brand called IF1, which is available at www.IF1.skin.